Neumora rises as Alzheimer’s drug shows promise in easing agitation

Shares of drug developer Neumora Therapeutics NMRA.O rise 11.45% to $1.81 premarket

Co says its experimental drug, NMRA-511, showed positive results in an early-stage study for treating agitation in people with Alzheimer's disease

Agitation is a distressing symptom that often leads to earlier long-term care placement, says co

Trial involved 80 patients; drug worked best in those with high anxiety levels - NMRA

Co says side effects mostly mild, including colds, urinary infections and headaches

Alzheimer’s is a brain disorder that causes memory loss and confusion

As of last close, stock down ~7% over the past year